Cytek Biosciences (CTKB) to Announce Quarterly Earnings on Wednesday

Cytek Biosciences (NASDAQ:CTKB) will likely be releasing its Q2 2026 results after the market closes on Wednesday, August 5th. Analysts expect the company to post earnings of ($0.02) per share and revenue of $47.31 million for the quarter. Investors may review the information on the company’s upcoming Q2 2026 earning results page for the latest details on the call scheduled for Wednesday, August 5, 2026 at 4:30 PM ET.

Cytek Biosciences (NASDAQ:CTKB) last released its earnings results on Thursday, May 7th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.08) by ($0.07). The firm had revenue of $44.13 million during the quarter, compared to analyst estimates of $44.23 million. Cytek Biosciences had a negative net margin of 36.25% and a negative return on equity of 10.07%. On average, analysts expect Cytek Biosciences to post $-0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Cytek Biosciences Trading Up 2.1%

Shares of CTKB opened at $4.31 on Tuesday. The firm’s fifty day simple moving average is $4.30 and its two-hundred day simple moving average is $4.44. Cytek Biosciences has a 12 month low of $3.28 and a 12 month high of $6.18. The stock has a market capitalization of $556.59 million, a P/E ratio of -7.56 and a beta of 1.17.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on CTKB. Morgan Stanley dropped their price objective on Cytek Biosciences from $6.00 to $5.50 and set an “equal weight” rating on the stock in a research note on Tuesday, May 12th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Cytek Biosciences in a research note on Wednesday, June 24th. Finally, Stephens lowered their target price on Cytek Biosciences from $5.50 to $4.75 and set an “overweight” rating for the company in a report on Wednesday, May 13th. Three equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $5.69.

Hedge Funds Weigh In On Cytek Biosciences

A number of institutional investors and hedge funds have recently made changes to their positions in CTKB. Boston Partners lifted its holdings in shares of Cytek Biosciences by 13,369.4% in the 4th quarter. Boston Partners now owns 5,008,309 shares of the company’s stock worth $25,297,000 after purchasing an additional 4,971,126 shares in the last quarter. Topline Capital Management LLC increased its stake in Cytek Biosciences by 255.7% during the 2nd quarter. Topline Capital Management LLC now owns 5,231,260 shares of the company’s stock valued at $17,786,000 after purchasing an additional 3,760,485 shares in the last quarter. Wellington Management Group LLP acquired a new position in Cytek Biosciences during the third quarter worth $8,817,000. Millennium Management LLC raised its holdings in Cytek Biosciences by 269.6% during the third quarter. Millennium Management LLC now owns 3,418,382 shares of the company’s stock worth $11,862,000 after buying an additional 2,493,610 shares during the last quarter. Finally, Russell Investments Group Ltd. lifted its stake in shares of Cytek Biosciences by 527.6% in the fourth quarter. Russell Investments Group Ltd. now owns 1,001,127 shares of the company’s stock valued at $5,056,000 after buying an additional 841,614 shares in the last quarter. Institutional investors own 69.46% of the company’s stock.

Cytek Biosciences Company Profile

Cytek Biosciences is a biotechnology company specializing in innovative cell analysis solutions. The firm develops and commercializes advanced spectral flow cytometry instruments and associated reagents designed to enable high-parameter single-cell analysis. Its technology platform offers researchers and clinicians enhanced sensitivity, resolution and flexibility compared to traditional flow cytometry methods.

The company’s core product portfolio includes the Aurora and Northern Lights spectral cytometry systems, which support simultaneous detection of up to 64 fluorescence parameters.